Hyperplasia News
-
Citrine Medicine Announces Approval of Wakix (pitolisant) for Named Patient Program in China
The narcolepsy drug Wakix can now be prescribed to patients in China with urgent unmet medical needs BOSTON, Mass., and Boao, Hainan, China, May 07, 2021 – Citrine Medicine, a China-based rare disease therapeutics company, today announced that the narcolepsy therapy Wakix® (pitolisant) has been approved by the Health Commission and Medical Products Administration of Hainan Province ...
-
RareStone Inc. Announces Strategic Collaboration with Tencent on a Service Ecosystem Focused on Rare Disease Patients in China
Holdings Limited (Tencent),based in Shenzhen,China,signed a strategic collaboration memorandum to develop a service ecosystem focused on rare disease patients in China. The combined effort will promote education of rare disease,focus social awareness on rare disease,and improve accessibility of medical information and services for rare disease by working together to provide innovative digital ...
-
Citrine medicine and Sinopharm group announce strategic partnership to broaden and accelerate access to rare disease drugs in china
Collaboration to focus on establishing supply chain and securing distribution channels for delivering rare disease therapies to patients across China BOSTON, Mass. and SHANGHAI, China, April 19, 2021 – Citrine Medicine, a China-based rare disease therapeutics company, and Sinopharm Group, a Chinese pharmaceutical company, today announced a strategic partnership to accelerate the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you